كلونازيبام (clonazepam)

# كلونازيبام (clonazepam) ## Overview Clonazepam is a high-potency, long-acting benzodiazepine with anticonvulsant, anxiolytic, and sedative properties. It acts as a positive allosteric modulator of the $GABA_A$ receptor. ## Primary Indications * **Seizure Disorders:** Absence seizures, Lennox-Gastaut syndrome, and myoclonic seizures. * **Panic Disorder:** With or without agoraphobia. * **Off-label:** Adjunctive treatment for acute mania, akathisia, and restless legs syndrome. ## Adult Dosing * **Seizure Disorders:** Initial dose 0.5 mg orally three times daily. Increase by 0.5–1 mg every 3 days until seizures are controlled or side effects become intolerable. **Maximum: 20 mg/day.** * **Panic Disorder:** Initial dose 0.25 mg twice daily. Increase to a target dose of 1 mg/day after 3 days. **Maximum: 4 mg/day.** ## Pediatric Dosing * **Seizure Disorders (Infants/Children up to 10 years or 30 kg):** Initial dose 0.01–0.03 mg/kg/day (not exceeding 0.05 mg/kg/day) divided into 2–3 doses. Increase gradually by 0.25–0.5 mg every 3 days. * **Maintenance:** 0.1–0.2 mg/kg/day divided into 3 doses. ## Dose Adjustments * **Hepatic Impairment:** Use caution; avoid in severe impairment. No specific guideline for dose reduction exists, but clinical titration is required. * **Renal Impairment:** No formal dosage adjustment required, but patients should be monitored for increased sensitivity to CNS effects. * **Geriatrics:** Start at the lowest possible dose (e.g., 0.25 mg) due to increased risk of falls, cognitive impairment, and paradoxical reactions. ## Contraindications * Known hypersensitivity to benzodiazepines. * Severe liver disease. * Acute narrow-angle glaucoma. * Concomitant use with opioids (black box warning for respiratory depression). ## Adverse Effects * **Common:** Somnolence, fatigue, ataxia, dizziness, and cognitive impairment. * **Serious:** Respiratory depression, physical dependence/withdrawal syndrome, paradoxical agitation, and suicidal ideation. ## Key Drug Interactions * **CNS Depressants (Opioids, Alcohol, Barbiturates):** Severe risk of additive CNS and respiratory depression. * **CYP3A4 Inducers (e.g., Carbamazepine, Phenytoin):** May decrease clonazepam plasma concentrations. * **CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir):** May increase clonazepam plasma concentrations. ## Monitoring * **Efficacy:** Frequency and severity of seizures or panic attacks. * **Safety:** CNS/respiratory status, signs of abuse/misuse, and liver function tests in long-term therapy. * **Withdrawal:** Monitor for tremors, anxiety, sweating, or seizures upon discontinuation. ## Clinical Pearls * **Tapering:** Never discontinue abruptly after chronic use to avoid withdrawal seizures. Taper slowly over weeks or months. * **Tolerance:** Anticonvulsant tolerance may develop within 1–6 months of chronic use. * **Pregnancy/Lactation:** Use only if potential benefits outweigh risks. Associated with neonatal withdrawal and potential teratogenicity. *** **Disclaimer:** This information is for educational purposes only. Always consult current clinical guidelines, institutional protocols, and the official package insert (FDA/local regulatory authority) before prescribing or administering medication.